Photo from academic.microsoft.com
Expert's summary: Checkmate 214 is a randomised trial comparing the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab (IN) in combination with sunitinib in previously untreated metastatic renal cell carcinoma (mRCC).… Click to show full abstract
Expert's summary: Checkmate 214 is a randomised trial comparing the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab (IN) in combination with sunitinib in previously untreated metastatic renal cell carcinoma (mRCC). The results showed significantly better outcomes with IN. This will change practice. Other studies investigating combinations of VEGF targeted therapy and ICIs are reporting, which will further impact outcomes.
Keywords:
cell carcinoma;
renal cell;
nivolumab plus;
plus ipilimumab
Journal Title: European urology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European urology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!